PMC:7195088 / 61370-61791 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"1830","span":{"begin":40,"end":48},"obj":"Species"},{"id":"1831","span":{"begin":54,"end":62},"obj":"Disease"},{"id":"1832","span":{"begin":75,"end":120},"obj":"Disease"},{"id":"1833","span":{"begin":141,"end":167},"obj":"Disease"},{"id":"1834","span":{"begin":207,"end":224},"obj":"Disease"},{"id":"1835","span":{"begin":246,"end":250},"obj":"Disease"},{"id":"1836","span":{"begin":255,"end":273},"obj":"Disease"},{"id":"1837","span":{"begin":383,"end":391},"obj":"Disease"}],"attributes":[{"id":"A1830","pred":"tao:has_database_id","subj":"1830","obj":"Tax:9606"},{"id":"A1831","pred":"tao:has_database_id","subj":"1831","obj":"MESH:C000657245"},{"id":"A1832","pred":"tao:has_database_id","subj":"1832","obj":"MESH:D060085"},{"id":"A1833","pred":"tao:has_database_id","subj":"1833","obj":"MESH:D061325"},{"id":"A1835","pred":"tao:has_database_id","subj":"1835","obj":"MESH:D012128"},{"id":"A1836","pred":"tao:has_database_id","subj":"1836","obj":"MESH:D009102"},{"id":"A1837","pred":"tao:has_database_id","subj":"1837","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"According to some recent evidence, some patients with COVID-19 may develop secondary haemophagocytic lymphohistiocytosis, an underrecognized hyperinflammatory syndrome characterized by a fulminant and fatal hypercytokinaemia, with development of ARDS and multiorgan failure [46,47,67]. Consequently, immunosuppressive and/or immunomodulatory therapies have been proposed to contrast COVID-19–associated hyperinflammation."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T356","span":{"begin":54,"end":62},"obj":"Disease"},{"id":"T357","span":{"begin":75,"end":120},"obj":"Disease"},{"id":"T358","span":{"begin":246,"end":250},"obj":"Disease"},{"id":"T359","span":{"begin":255,"end":273},"obj":"Disease"},{"id":"T360","span":{"begin":383,"end":391},"obj":"Disease"}],"attributes":[{"id":"A356","pred":"mondo_id","subj":"T356","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A357","pred":"mondo_id","subj":"T357","obj":"http://purl.obolibrary.org/obo/MONDO_0015542"},{"id":"A358","pred":"mondo_id","subj":"T358","obj":"http://purl.obolibrary.org/obo/MONDO_0006502"},{"id":"A359","pred":"mondo_id","subj":"T359","obj":"http://purl.obolibrary.org/obo/MONDO_0043726"},{"id":"A360","pred":"mondo_id","subj":"T360","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"According to some recent evidence, some patients with COVID-19 may develop secondary haemophagocytic lymphohistiocytosis, an underrecognized hyperinflammatory syndrome characterized by a fulminant and fatal hypercytokinaemia, with development of ARDS and multiorgan failure [46,47,67]. Consequently, immunosuppressive and/or immunomodulatory therapies have been proposed to contrast COVID-19–associated hyperinflammation."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T335","span":{"begin":185,"end":186},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"According to some recent evidence, some patients with COVID-19 may develop secondary haemophagocytic lymphohistiocytosis, an underrecognized hyperinflammatory syndrome characterized by a fulminant and fatal hypercytokinaemia, with development of ARDS and multiorgan failure [46,47,67]. Consequently, immunosuppressive and/or immunomodulatory therapies have been proposed to contrast COVID-19–associated hyperinflammation."}

{"project":"LitCovid-sentences","denotations":[{"id":"T446","span":{"begin":0,"end":285},"obj":"Sentence"},{"id":"T447","span":{"begin":286,"end":421},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"According to some recent evidence, some patients with COVID-19 may develop secondary haemophagocytic lymphohistiocytosis, an underrecognized hyperinflammatory syndrome characterized by a fulminant and fatal hypercytokinaemia, with development of ARDS and multiorgan failure [46,47,67]. Consequently, immunosuppressive and/or immunomodulatory therapies have been proposed to contrast COVID-19–associated hyperinflammation."}

{"project":"2_test","denotations":[{"id":"32360444-32192578-22369810","span":{"begin":281,"end":283},"obj":"32192578"}],"text":"According to some recent evidence, some patients with COVID-19 may develop secondary haemophagocytic lymphohistiocytosis, an underrecognized hyperinflammatory syndrome characterized by a fulminant and fatal hypercytokinaemia, with development of ARDS and multiorgan failure [46,47,67]. Consequently, immunosuppressive and/or immunomodulatory therapies have been proposed to contrast COVID-19–associated hyperinflammation."}